The Micro study is a small, exploratory Phase 0 experimental medicine study seeking to test the hypotheses that ADS032 can attenuate components of the immune system (alveolar macrophages) when delivered at microdose concentrations.
This study will specifically address whether ADS032 when delivered in situ in the distal human inflamed lung is active in the target cell of interest in a relevant patient population. We will explore this in suspected or confirmed ILD patients and in bronchiectasis patients and also in patients who are having planned lung resections. This study will commence in the summer of 2023 in NHS Lothian and is predicted to take 6 months to complete.
We are also currently setting up a microdosing platform where we will be able to dose multiple agents in the lung at the same time.